Get the Weekly Intelligence Brief — top committee picks every Sunday.
BLLN · NASDAQ · STOCK

BillionToOne (BLLN) Stock Analysis

Healthcare Updated October 10, 2026
$98.15
52W $61.96 – $150.44
51/100
$4.51B
142.1
0.34
AI Committee Verdict
Watch
51/100
Conviction: Contested · 50% agreement · 6 analysts
+53.2%
-10.2%
5.24:1
Contested

Is BLLN Bullish or Bearish?

Mixed. Innellis AI committee rates BillionToOne, Inc. (BLLN) Watch with a composite score of 51/100 , based on 6 analysts with 50% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +9.45 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -10.55 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Low leverage (debt-to-equity 0.14) -- balance sheet can absorb a shock — Risk
Bear Case
  • P/E of 122.7 is expensive by classic value standards — Value
  • Price-to-book of 7.8x prices in significant intangible value — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • MACD histogram negative -- bearish momentum — Technical
  • Bollinger bandwidth of 33.1% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
51/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 92%
of 192 Healthcare peers
Value Analyst bearish
40 / 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 122.7 is expensive by classic value standards
Growth Analyst bearish
35 / 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst neutral
58 / 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.14) -- balance sheet can absorb a shock
− Bollinger bandwidth of 33.1% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 48.9 to 50.5.

Analyst-level changes:
  • Risk Analyst: +1 bearish signal(s).
  • Technical Analyst: stance bearish->neutral; score 38->48 (+10).
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
36.9
Neutral
MACD Histogram
-2.138
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$88.19
Resistance
$150.35
Bollinger %B
0.22
Inside Bands
Price vs Moving Averages
EMA 9
$102.69 Below
EMA 21
$105.18 Below
EMA 50
$105.92 Below
EMA 200
$101.90 Below

Fundamental Analysis

Valuation
33
Growth
52
Profitability
40
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio 142.1×
P/B Ratio 8.48×
PEG Ratio 0.02
Dividend Yield 0.00%
52W High $150.44
52W Low $61.96
Quality & Growth
ROE 155.3%
ROA 117.8%
Gross Margin 7126.7%
Operating Margin 1089.6%
Revenue Growth YoY —
Debt / Equity 0.27
AI Fundamental Assessment
P/E ratio of 142.1 (rich relative to a 15-40x range); Price-to-book of 8.5x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 1.6%; Return on assets of 1.2%; Net margin of 8.4%; Gross margin of 71.3%; Current ratio of 11.69 (healthy short-term liquidity); Debt-to-equity of 0.27; Free cash flow per share is positive (0.71); Most recent quarter missed estimates by 20.2%; EPS growth decelerating (+209.1% -> -55.9% QoQ); Analyst estimates rising over recent quarters
Get the Full BLLN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime